Holen Sie sich die Stockscreener-App
94.84
0.27%
0.24
Schlusskurs vom Vortag:
$94.60
Offen:
$94.62
24-Stunden-Volumen:
979.53K
Relative Volume:
0.48
Marktkapitalisierung:
$7.17B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-24.01
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+0.27%
1M Leistung:
+37.69%
6M Leistung:
+109.48%
1J Leistung:
+79.58%
1-Tages-Spanne:
$94.58
$94.88
1-Wochen-Bereich:
$94.38
$95.06
52-Wochen-Spanne:
$33.19
$95.06
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.84 | 7.17B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.99 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.74 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
483.43 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
831.85 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.16 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-08-25 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Will Merus N.V. stock sustain high P E ratios2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
What risks investors should watch in Merus N.V. stockWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com
Can Merus N.V. stock double in next 5 yearsJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
What market sentiment indicators show for Merus N.V. (2GH) stock2025 Market Overview & Real-Time Volume Analysis - newser.com
Is Merus N.V. stock a buy before product launches2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Why Merus N.V. stock remains on buy listsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Is Merus N.V. stock resilient to inflationJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Market reaction to Merus N.V.’s recent newsWeekly Market Outlook & Stock Portfolio Risk Control - newser.com
Can Merus N.V. (2GH) stock sustain revenue momentumDay Trade & AI Enhanced Execution Alerts - newser.com
Key metrics from Merus N.V.’s quarterly dataMarket Performance Report & High Accuracy Trade Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearTrade Analysis Report & Short-Term Trading Opportunity Alerts - newser.com
Why Merus N.V. stock appeals to dividend seekers2025 Price Targets & Capital Protection Trade Alerts - newser.com
Merus N.V.’s Zenocutuzumab Study Termination: Market Implications - TipRanks
Will Merus N.V. stock deliver better than expected guidanceWeekly Stock Report & Technical Confirmation Trade Alerts - newser.com
Is Merus N.V. stock attractive for income investorsEarnings Performance Report & Fast Entry Momentum Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stock2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
2.31%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):